Quick Takeaways
- ORBIMED ADVISORS LLC filed SCHEDULE 13G/A for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX).
- Disclosed ownership: 6.4%.
- Date of event: 31 Dec 2025.
ORBIMED ADVISORS LLC - 31 Dec 2025 SCHEDULE 13G/A Report for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX)
- Filing Manager
- ORBIMED ADVISORS LLC
- Reporting Manager
- OrbiMed Advisors LLC
- Symbol
- AVTX
- Shares outstanding
- 18,551,563 shares
- Disclosed Ownership
- 1,187,300 shares
- Ownership
- 6.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 18:13:19 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIMED ADVISORS LLC disclosed 6.4% ownership in Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 17 Feb 2026, 18:13.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 6.4% | 1,187,300 | 0 | 1,187,300 | /s/ Carl L. Gordon | Carl L. Gordon / Member of OrbiMed Advisors LLC |